Focused On-demand Library for Ras GTPase-activating protein 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O43374

UPID:

RASL2_HUMAN

Alternative names:

Calcium-promoted Ras inactivator; Ras p21 protein activator 4; RasGAP-activating-like protein 2

Alternative UPACC:

O43374; O60286; Q14CQ4; Q86UW3; Q96QU0

Background:

Ras GTPase-activating protein 4, also known as Calcium-promoted Ras inactivator, plays a pivotal role in cellular signaling by acting as a Ca(2+)-dependent Ras GTPase-activating protein. It effectively switches off the Ras-MAPK pathway following stimuli that elevate intracellular calcium levels. Additionally, it serves as an adaptor for Cdc42 and Rac1 during FcR-mediated phagocytosis, highlighting its versatile role in cellular dynamics.

Therapeutic significance:

Understanding the role of Ras GTPase-activating protein 4 could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways and cellular processes underscores its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.